Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial.
about
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDPharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulantsThe adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorderImmediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adultsOptimal management of ADHD in older adultsMeta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adultsChanges in behavior as side effects in methylphenidate treatment: review of the literatureEfficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adultsSafety of therapeutic methylphenidate in adults: a systematic review of the evidenceAttention-deficit/hyperactivity disorder in adults: evidence-based recommendations for managementThe social and cultural construction of psychiatric knowledge: an analysis of NICE guidelines on depression and ADHD.Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsDouble-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder.Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial.The severity of ADHD and eating disorder symptoms: a correlational study.Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD.Clinical assessment and treatment of attention deficit hyperactivity disorder in adults.Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomisePharmacological treatment of attention-deficit/hyperactivity disorder in adults.Risk of methylphenidate-induced prehypertension in normotensive adult smokers with attention deficit hyperactivity disorder.Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology.Treatment of adult ADHD: is current knowledge useful to clinicians?Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder.Current issues around the pharmacotherapy of ADHD in children and adults.Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.Review of literature of attention-deficit/hyperactivity disorder with comorbid eating disorders.Distinguishing comorbidity and successful management of adult ADHD.Toward quality care in ADHD: defining the goals of treatment.The safety and efficacy of methylphenidate and dexmethylphenidate in adults with attention deficit/hyperactivity disorder.An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder.The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis.ADHD in old age: a review of the literature and proposal for assessment and treatment.The relation between procrastination and symptoms of attention-deficit hyperactivity disorder (ADHD) in undergraduate students.Differences in Psychiatric Problems and Criminality Between Individuals Treated With Central Stimulants Before and After Adulthood.Addiction in developmental perspective: influence of conduct disorder severity, subtype, and attention-deficit hyperactivity disorder on problem severity and comorbidity in adults with opioid dependence.Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial.Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults.Intellectual functioning in relation to autism and ADHD symptomatology in children and adolescents with 22q11.2 deletion syndrome.ADHD in adults: a study of clinical characteristics, impairment and comorbidity.
P2860
Q21260332-B7A36A2D-9BF4-4158-B623-507FDEEC3A24Q22241445-3FB9463F-B928-4712-AC5F-EF5BA764A3FDQ22241830-477CA45B-63CC-4894-9858-7ED875827E34Q26471999-74263C57-4BD0-4976-BDC3-4D980B99AE11Q26774425-176DFF64-A6B1-4408-ACB9-D0B7CACCD485Q26858868-462AFCC7-DCE4-4619-9A3C-6C1F682AD715Q28078623-77497A11-73B4-4BC7-914E-D99C8CA222C9Q28246506-A68FFF22-C06E-49CC-AF57-BDEB10AC7BD4Q28282264-61044A69-DE1A-4AF8-B4C3-EADC1A33B02AQ28295525-EB49628E-FD04-4E91-A555-E83ECE8E42F7Q30428292-2ACECCA1-4E0C-470A-87EE-216FA5C52764Q34085116-7A1642E1-31C8-4F3C-8860-A405D0A5B8F6Q34220004-7847CB48-EBD0-4706-BB96-9634484E8662Q34247801-33357B34-C8F6-4C26-95EF-705973A125B1Q34561459-B699C551-5758-4519-BEB7-01225FF73B7DQ34572514-79111EFA-9322-4CF1-A9A4-17FBC474D582Q35627332-40EBBDEC-EBFA-41C0-A053-04EE90C19FCBQ36198624-61F21084-F60E-493D-8012-954136C75ECCQ36364178-08C8F79B-0C92-4EA3-9F5B-C7804FDB427FQ36491834-51BD9F8C-4BDF-4956-BFCD-6CD0CD5CB45BQ36567686-B6E092AC-B030-4CE8-B67D-A88FA2F35C6CQ36648476-0E285FF3-8D24-4672-AC0F-BCE511BBAE45Q36836781-834965E1-55DB-403D-BAD3-DCDD1791E065Q37194205-54C357FF-34A4-4B40-A538-A64CF24DCB54Q37314533-43DF1C00-663A-4C09-BD69-31C316F94DBDQ37354631-DCEDE739-C87E-4599-BB58-3F2550DA5EB2Q37367929-70D48B70-C6A9-440F-9869-44B70197B5F9Q38002290-8621D7A6-4BA0-40EB-9B5B-C8C60E5AAC8EQ38082894-0F63A24F-91CC-462B-A2DB-058544A394AEQ38122148-3FEF3EAA-88C2-4E91-A718-5C57C1D2A6B9Q38214174-A4B74B27-0012-41CA-8792-AAA7ACC96A6DQ38793954-E309B458-3F9E-46D5-A0CA-337CB117845FQ38873722-4221F5DE-EDCA-4F2E-8F95-BF054D5E9CD4Q39165195-32947074-11D7-4F03-BE05-2EBA4833D138Q41185472-9DB79A9C-A1B6-4AC3-9F16-264500FBF556Q44333067-F679ECD1-6CF8-418E-A1EB-55F1B6C77F62Q46727017-A5200AA5-9154-4935-9ED4-73E3163936F1Q47414856-A9550C83-A11F-4617-AF83-9BB2E59A524AQ48327735-6F2CEDE2-E1DB-4428-8818-2513E9B44820Q48456099-6FF53740-39B2-49E5-88FB-BA7676649A4E
P2860
Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Efficacy and safety of methylp ...... double-blind cross-over trial.
@en
type
label
Efficacy and safety of methylp ...... double-blind cross-over trial.
@en
prefLabel
Efficacy and safety of methylp ...... double-blind cross-over trial.
@en
P2093
P1476
Efficacy and safety of methylp ...... double-blind cross-over trial.
@en
P2093
Boonstra AM
Buitelaar JK
Van der Linden PD
P304
P356
10.1017/S0033291703001776
P407
P577
2004-08-01T00:00:00Z